Combination of Topical Heparin and Levomenol in the Treatment of Atopic Dermatitis: A SCORing Atopic Dermatitis (SCORAD) Analysis
<p>Reduction in inflamed body area relative to baseline, after four and eight weeks of treatment (<span class="html-italic">p</span> value vs. control; * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, **** <span class="html-italic">p</span> ≤ 0.0001).</p> "> Figure 2
<p>Within-group improvement in skin-related symptoms: (<b>A</b>) erythema; (<b>B</b>) edema/papulation; (<b>C</b>) excoriations; (<b>D</b>) oozing/crust formation; (<b>E</b>) lichenification; (<b>F</b>) dryness of unaffected skin (n.s.: not significant).</p> "> Figure 2 Cont.
<p>Within-group improvement in skin-related symptoms: (<b>A</b>) erythema; (<b>B</b>) edema/papulation; (<b>C</b>) excoriations; (<b>D</b>) oozing/crust formation; (<b>E</b>) lichenification; (<b>F</b>) dryness of unaffected skin (n.s.: not significant).</p> "> Figure 2 Cont.
<p>Within-group improvement in skin-related symptoms: (<b>A</b>) erythema; (<b>B</b>) edema/papulation; (<b>C</b>) excoriations; (<b>D</b>) oozing/crust formation; (<b>E</b>) lichenification; (<b>F</b>) dryness of unaffected skin (n.s.: not significant).</p> "> Figure 2 Cont.
<p>Within-group improvement in skin-related symptoms: (<b>A</b>) erythema; (<b>B</b>) edema/papulation; (<b>C</b>) excoriations; (<b>D</b>) oozing/crust formation; (<b>E</b>) lichenification; (<b>F</b>) dryness of unaffected skin (n.s.: not significant).</p> "> Figure 3
<p>Percentage of patients showing improvements from “severe” or “moderate” to “mild” or “absent” after eight weeks of treatment (* <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, **** <span class="html-italic">p</span> ≤ 0.0001, # <span class="html-italic">p</span> = 0.05).</p> "> Figure 4
<p>Reduction in sleep loss during the study compared to baseline after four and eight weeks of treatment (* <span class="html-italic">p</span> < 0.05, **** <span class="html-italic">p</span> ≤ 0.0001).</p> ">
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Within-Group Analyses of Individual SCORAD Parameters
2.3. Statistics
3. Results
3.1. SCORAD Parameters Part A: Inflamed Body Area
3.2. SCORAD Parameters Part B: Severity and Improvement of Skin-Related Symptoms
3.3. SCORAD Parameters Part C: Sleeplessness
3.4. Correlation Between Pruritus/Inflamed Area and Pruritus/Sleep Loss
4. Discussion and Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Schön, M.P.; Buhl, T. Symptome, Pathogenese und Therapie der Neurodermitis. Pharmakon 2019, 7, 19–23. [Google Scholar]
- Wollenberg, A.; Kinberger, M.; Arents, B.; Aszodi, N.; Avila Valle, G.; Barbarot, S.; Bieber, T.; Brough, H.A.; Calzavara Pinton, P.; Christen-Zach, S.; et al. European guideline (EuroGuiDerm) on atopic eczema: Part I—Systemic therapy. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1409–1431. [Google Scholar] [CrossRef] [PubMed]
- Werfel, T.; Heratizadeh, A.; Aberer, W.; Ahrens, F.; Augustin, M.; Biedermann, T.; Diepgen, T.; Folster-Holst, R.; Gieler, U.; Kahle, J.; et al. S2k guideline on diagnosis and treatment of atopic dermatitis—Short version. J. Dtsch. Dermatol. Ges. 2016, 14, 92–106. [Google Scholar] [CrossRef] [PubMed]
- Arenberger, P.; Buchvald, J. Placebo-kontollierte Doppelblindstudie zur Beurteilung von Wirksamkeit und Sicherheit einer Creme mit den Wirkstoffen Levomenol und Heparin bei Patienten mit atopischem Ekzem. Ref. Vybr. Dermatovenerol. 2005, 47, 18–21. [Google Scholar]
- Arenberger, P.; Arenbergerova, M.; Drozenova, H.; Hladikova, M.; Holcova, S. Effect of topical heparin and levomenol on atopic dermatitis: A randomized four-arm, placebo-controlled, double-blind clinical study. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 688–694. [Google Scholar] [CrossRef] [PubMed]
- Arenberger, P.; Drozenova, H.; Hladicova, M.; Holcova, S. Additive Wirkung von Heparin und Levomenol bei Neurodermitis. Aktuelle Dermatol. 2010, 36, 217–221. [Google Scholar] [CrossRef]
- Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993, 186, 23–31. [CrossRef] [PubMed]
- Schmidt, M. Topical treatment of atopic dermatitis with heparin and levomenol: A survey of dermatologist’s experience. In Proceedings of the GSPHPM2022: Global Summit on Public Health and Preventive Medicine, München, Germany, 26–28 May 2022. [Google Scholar] [CrossRef]
- Ferreira Chacon, J.M.; Mello de Andrea, M.L.; Blanes, L.; Ferreira, L.M. Effects of topical application of 10,000 IU heparin on patients with perineal dermatitis and second-degree burns treated in a public pediatric hospital. J. Tissue Viability 2010, 19, 150–158. [Google Scholar] [CrossRef]
- Dockhorn, R.J. Topical heparin in the treatment of eczema. Ann. Allergy 1970, 28, 573–579. [Google Scholar]
- Dougherty, T.F.; Dolowitz, D.A. Physiologic actions of heparin not related to blood clotting. Am. J. Cardiol. 1964, 14, 18–24. [Google Scholar] [CrossRef] [PubMed]
- Russell, K.; Jacob, S.E. Bisabolol. Dermatitis 2010, 21, 57–58. [Google Scholar] [CrossRef]
- Veraldi, S.; De Micheli, P.; Schianchi, R.; Lunardon, L. Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent. J. Drugs Dermatol. 2009, 8, 537–539. [Google Scholar] [PubMed]
- Rullo, V.E.; Segato, A.; Kirsh, A.; Sole, D. Severity scoring of atopic dermatitis: A comparison of two scoring systems. Allergol. Immunopathol. 2008, 36, 205–211. [Google Scholar] [CrossRef]
- Li, G.; Wu, H.; Sun, L.; Cheng, K.; Lv, Z.; Chen, K.; Qian, F.; Li, Y. (-)-alpha-Bisabolol Alleviates Atopic Dermatitis by Inhibiting MAPK and NF-kappaB Signaling in Mast Cell. Molecules 2022, 27, 3985. [Google Scholar] [CrossRef]
- Ramazani, E.; Akaberi, M.; Emami, S.A.; Tayarani-Najaran, Z. Pharmacological and biological effects of alpha-bisabolol: An updated review of the molecular mechanisms. Life Sci. 2022, 304, 120728. [Google Scholar] [CrossRef] [PubMed]
- Katakkar, S.B. Use of heparin as a topical antithrombotic and antiinflammatory agent. J. Natl. Cancer Inst. 1993, 85, 1865–1866. [Google Scholar] [CrossRef]
- Utsunomiya, R.; Dai, X.; Murakami, M.; Masuda, K.; Okazaki, H.; Tsuda, T.; Mori, H.; Shiraishi, K.; Tohyama, M.; Sayama, K. Heparinoid suppresses Der p-induced IL-1beta production by inhibiting ERK and p38 MAPK pathways in keratinocytes. Exp. Dermatol. 2018, 27, 981–988. [Google Scholar] [CrossRef]
- Völkl, K.P.; Konerding, M.A.; Kroll, M. Wirkung von topischem Heparin auf Histamin-induzierte Quaddeln. Eine Doppelblindstudie. Fortschr. Med. 1991, 109, 462–464. [Google Scholar]
- Yoshida, Y.; Hirama, A.; Hashimoto, K.; Sato, T.; Yokota, N.; Saeki, H.; Kishida, M.; Nakamura, H.; Kanakubo, A.; Tsuruoka, S. Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study. J. Dermatol. 2021, 48, 1327–1335. [Google Scholar] [CrossRef]
Treatment Group | n | Baseline | Week 4 | Week 8 |
---|---|---|---|---|
Combination | 79 | 29.38 ± 18.96 | 16.90 ± 10.82 | 10.78 ± 10.10 |
Improvement vs. baseline | 12.48 ± 12.21 | 18.59 ± 16.14 | ||
Improvement vs. control | 5.27 ± 1.38 | 7.77 ± 1.48 | ||
p value vs. control | p = 0.0002 | p = 3.2 × 10−5 | ||
Levomenol | 80 | 25.55 ± 18.43 | 20.64 ± 15.49 | 15.53 ± 11.97 |
Improvement vs. baseline | 4.91 ± 7.06 | 10.03 ± 10.55 | ||
Improvement vs. control | 1.14 ± 1.02 | 3.80 ± 1.25 | ||
p value vs. control | p = 0.27 (n.s.) | p = 0.003 | ||
Heparin | 78 | 23.08 ± 15.97 | 17.55 ± 12.07 | 13.31 ± 9.29 |
Improvement vs. baseline | 5.53 ± 6.57 | 9.77 ± 10.56 | ||
Improvement vs. control | 2.29 ± 0.84 | 4.18 ± 1.19 | ||
p value vs. control | p = 0.01 | p = 0.001 | ||
Control | 41 | 19.29 ± 16.77 | 17.34 ± 14.91 | 15.7 ± 14.35 |
Improvement vs. baseline | 1.95 ± 3.14 | 3.54 ± 3.98 |
Treatment Group | n | Erythema | Edema/Papulation | Excoriations | Oozing/Crust | Lichenification | Skin Dryness |
---|---|---|---|---|---|---|---|
Combination | 79 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 90.4% |
n = 66 (83.5%) | n = 24 (30.4%) | n = 58 (73.4%) | n = 14 (17.7%) | n = 15 (19.0%) | n = 52 (65.8%) | ||
p < 0.0001 | p = 0.016 | p = 0.0001 | n.s. (p > 0.05) | n.s. (p > 0.05) | p = 0.001 | ||
Levomenol | 80 | 97.2% | 95.0% | 77.8% | 92.9% | 81.8% | 65.4% |
n = 71 (88.8%) | n = 20 (25.0%) | n = 45 (56.3%) | n = 14 (17.5%) | n = 11 (13.8%) | n = 52 (65.0%) | ||
p = 0.001 | p = 0.06 (n.s.) | p = 0.003 | n.s. (p > 0.05) | n.s. (p > 0.05) | n.s. (p > 0.05) | ||
Heparin | 78 | 90.6% | 100.0% | 86.0% | 100.0% | 100.0% | 74.0% |
n = 53 (68.0%) | n = 16 (20.5%) | n = 43 (55.1%) | n = 14 (18.0%) | n = 6 (7.7%) | n = 50 (64.1%) | ||
p = 0.05 | p = 0.03 | p = 0.0002 | n.s. (p > 0.05) | n.s. (p > 0.05) | n.s. (p > 0.05) | ||
Control | 40 | 73.1% | 50.0% | 36.8% | 87.5% | 100.0% | 53.8% |
n = 26 (63.4%) | n = 4 (9.8%) | n = 19 (46.3%) | n = 8 (19.5%) | n = 2 (4.9%) | n = 26 (63.4%) |
Treatment Group | n | Baseline | Week 4 | Week 8 |
---|---|---|---|---|
Combination | 79 | 14.42 ± 13.21 | 8.85 ± 4.84 | 5.99 ± 3.40 |
Improvement vs. baseline | 5.57 ± 10.87 | 8.43 ± 12.34 | ||
Improvement vs. control | 1.20 ± 0.71 | 3.03 ± 0.69 | ||
p value vs. control | p = 0.09 (n.s.) | p = 2.4 × 10−6 | ||
Levomenol | 80 | 10.84 ± 11.22 | 9.69 ± 8.80 | 8.69 ± 7.85 |
Improvement vs. baseline | 1.15 ± 4.26 | 2.15 ± 6.00 | ||
Improvement vs. control | 0.02 ± 0.71 | 0.85 ± 0.70 | ||
p value vs. control | p = 0.97 (n.s.) | p = 0.23 (n.s.) | ||
Heparin | 78 | 13.99 ± 12.88 | 10.92 ± 10.20 | 8.06 ± 7.58 |
Improvement vs. baseline | 3.06 ± 8.05 | 5.92 ± 9.36 | ||
Improvement vs. control | 0.57 ± 1.16 | 2.15 ± 0.94 | ||
p value vs. control | p = 0.62 (n.s.) | p = 0.024 | ||
Control | 41 | 7.98 ± 8.30 | 7.44 ± 6.43 | 7.54 ± 6.23 |
Improvement vs. baseline | 0.54 ± 5.73 | 0.44 ± 4.68 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hladíková, M.; Schmidt, M. Combination of Topical Heparin and Levomenol in the Treatment of Atopic Dermatitis: A SCORing Atopic Dermatitis (SCORAD) Analysis. Dermato 2024, 4, 205-216. https://doi.org/10.3390/dermato4040018
Hladíková M, Schmidt M. Combination of Topical Heparin and Levomenol in the Treatment of Atopic Dermatitis: A SCORing Atopic Dermatitis (SCORAD) Analysis. Dermato. 2024; 4(4):205-216. https://doi.org/10.3390/dermato4040018
Chicago/Turabian StyleHladíková, Marie, and Mathias Schmidt. 2024. "Combination of Topical Heparin and Levomenol in the Treatment of Atopic Dermatitis: A SCORing Atopic Dermatitis (SCORAD) Analysis" Dermato 4, no. 4: 205-216. https://doi.org/10.3390/dermato4040018
APA StyleHladíková, M., & Schmidt, M. (2024). Combination of Topical Heparin and Levomenol in the Treatment of Atopic Dermatitis: A SCORing Atopic Dermatitis (SCORAD) Analysis. Dermato, 4(4), 205-216. https://doi.org/10.3390/dermato4040018